Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody

Antiviral Therapy

Volumn 10, Issue 5, 2005, Pages 681-690

  Wang, Xiliang ^a   Ni, Bing ^b   Du, Xinan ^a   Zhao, Guangyu ^a   Gao, Wenda ^c   Shi, Xinfu ^a   Zhang, Songle ^a   Zhang, Liangyan ^a   Wang, Dong ^a   Luo, Deyan ^a   Xing, Li ^a   Jiang, Haiyan ^a   Li, Wanling ^b   Jiang, Man ^b   Mao, Liwei ^b   He, Yangdong ^b   Xiao, Yu ^b   Wu, Yuzhang ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIODACTYLA; CELL PROTECTION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; FEMALE; HORSE; MAMMAL CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HORSES; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAPERITONEAL; MICE; NEUTRALIZATION TESTS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELLS;

EID: 24044460153     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS & Poon LL. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302:276-278.
2. Yan L, Velikanov M, Flook P, Zheng W, Szalma S & Kahn S. Assessment of putative protein targets derived from the SARS genome. FEBS Letters 2003; 554:257-263.
3. Enserink M &c Normile D. Infectious diseases. Search for SARS origins stalls. Science 2003; 302:766-767.
4. Lai MM. SARS virus: the beginning of the unraveling of a new coronavirus. Journal of Biomedical Science 2003; 10:664-675.
5. Watt G, Kantipong P, Jongsakul K, de Souza M & Burnouf T. Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study. QJM 2001; 94:599-607.
6. Savoldo B, Goss J, Liu Z, Huls MH, Doster S, Gee AP, Brenner MK, Heslop HE & Rooney CM. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001; 72:1078-1086.
7. Chiba T, Yokosuka O, Goto S, Fukai K, Imazeki F, Shishido H, Narita M & Saisho H. Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. European Journal of Haematology 2003; 71:220-223.
8. Ferrantelli F, Rasmussen RA, Hofmann-Lehmann R, Xu W, McClure HM & Ruprecht RM. Do not underestimate the power of antibodies - lessons from adoptive transfer of antibodies against HIV. Vaccine 2002; 20(Suppl 4):A61-A65.
9. Dahmen U, Dirsch O, Li J, Fiedle M, Lu M, Rispeter K, Picucci M, Broelsch CE & Roggendorf M. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 2004; 77:965-972.
10. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G & Sung JJ. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical Microbiology & Infection 2004; 10:676-678.
11. Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S & Murphy B. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. Journal of Virology 2004; 78:3572-3577.
12. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, Feng J, Yang D, Gao G & Jin G. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochemical & Biophysical Research Communications 2005; 333:186-193.
13. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M & Marasco WA. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. Journal of Virology 2005; 79:5900-5906.
14. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R & Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Medicine 2004; 10:871-875.
15. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M & Marasco WA. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proceedings of the National Academy of Sciences, USA 2004; 101:2536-2541.
16. ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J & Osterhaus AD. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004; 363:2139-2141.
17. Otero R, Gutierrez JM, Rojas G, Nunez V, Diaz A, Miranda E, Uribe AF, Silva JF, Ospina JG, Medina Y, Toro MF, Garcia ME, Leon G, Garcia M, Lizano S, De La Torre J, Marquez J, Mena Y, Gonzalez N, Arenas LC, Puzon A, Blanco N, Sierra A, Espinal ME & Lozano R. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon 1999; 37:895-908.
18. Sjostrom L, al Abdulla IH, Rawat S, Smith DC & Landon J. A comparison of ovine and equine antivenoms. Toxicon 1994; 32:427-433.
19. Fernandes I, Lima EX, Takehara HA, Moura-da-Silva AM, Tanjoni I & Gutierrez JM. Horse IgG isotypes and cross-neutralization of two snake antivenoms produced in Brazil and Costa Rica. Toxicon 2000; 38:633-644.
20. Carroll SB, Thalley BS, Theakston RD & Laing G. Comparison of the purity and efficacy of affinity purified avian antivenoms with commercial equine crotalid antivenoms. Toxicon 1992; 30:1017-1025.
21. Maya DC, Vasantha BM & Krishnan LK. Development of viper-venom antibodies in chicken egg yolk and assay of their antigen binding capacity. Toxicon 2002; 40:857-861.
22. Braz A, Minozzo J, Abreu JC, Gubert IC & Chavez-Olortegui C. Development and evaluation of the neutralizing capacity of horse antivenom against the Brazilian spider Loxosceles intermedia. Toxicon 1999; 37:1323-1328.
23. Da Silva WD, Campos CM, Goncalves LR, Sousa-e-Silva MC, Higashi HG, Yamagushi IK & Kelen EM. Development of an antivenom against toxins of Lonomia obliqua caterpillars. Toxicon 1996; 34:1045-1049.
24. Raghavachar A. Pure red cell aplasia: review of treatment and proposal for a treatment strategy. Blut 1990; 61:47-51.
25. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs 2003; 17:147-154.
26. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S, Socie G, Tichelli A, Passweg J, Hows J, Raghavachar A, Locasciulli A & Bacigalupo A. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999; 93:2191-2195.
27. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, Gabbas A, Dufour C, Arcese W, Testi G, Broccia G, Carotenuto M, Coser P, Barbui T, Leoni P & Ferster A. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95:1931-1934.
28. Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J & Kraft GH. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003; 102:2364-2372.
29. Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sundernaus J, Furst DE & McSweeney PA. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biology of Blood & Marrow Transplantation 2003; 9:583-591.
30. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT & Marsh JC. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. British Journal of Haematology 2003; 120:679-684.
31. Lang J, Attanath P, Quiambao B, Singhasivanon V, Chanthavanich P, Montalban C, Lutsch C, Pepin-Covatta S, Le Mener V, Miranda M & Sabchareon A. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, vero-cell rabies vaccine. Acta Tropica 1998; 70:317-333.
32. Gilmour TM, Riley JN, Moser DL & McNally-Heintzelman KM. Solubility studies of albumin protein solders used for laser-assisted tissue repair. Biomedical Sciences Instrumentation 2002; 38:345-350.
33. Buchholz UJ, Bukreyev A, Yang L, Lamirande EW, Murphy BR, Subbarao K & Collins PL. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences, USA 2004; 101:9804-9809.
34. Chen YJ, Gao G, Bao YM, Lopez R, Wu JM, Cai T, Ye ZQ, Gu XC & Luo JC. Initial analysis of complete genome sequences of SARS coronavirus. Acta Genetica Sinica 2003; 30:493-500.
35. Zeng FY, Chan CW, Chan MN, Chen JD, Chow KY, Hon CC, Hui KH, Li J, Li VY, Wang CY, Wang PY, Guan Y, Zheng B, Poon LL, Chan KH, Yuen KY, Peiris JS & Leung FC. The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39). Experimental Biology & Medicine 2003; 228:866-873.
36. Zhang WG, Li JQ & Zhou HM. Genomic characterization of SARS coronavirus: a novel member of coronavirus. Acta Genetica Sinica 2003; 30:501-508.
37. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ & Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394-1399.
38. Pavlovic-Lazetic GM, Mitic NS & Beljanski MV. Bioinformatics analysis of SARS coronavirus genome polymorphism. BMC Bioinformatics 2004; 5:65.
39. Keller MA & Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clinical Microbiology Reviews 2000; 13:602-614.